The most ardently debated issue with regard to developing countries has been the question whether increased patent protection under the rules of the TRIPS Agreement impedes access to affordable medicines in poor countries.
The most ardently debated issue with regard to developing countries has been the question whether increased patent protection under the rules of the TRIPS Agreement impedes access to affordable medicines in poor countries.